您的购物车当前为空
别名 F1013
EP1013 is a broad-spectrum selective inhibitor of Caspase used in the study of type 1 diabetes.

EP1013 is a broad-spectrum selective inhibitor of Caspase used in the study of type 1 diabetes.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 25 mg | ¥ 6,320 | 8-10周 | |
| 50 mg | ¥ 8,210 | 8-10周 | |
| 100 mg | ¥ 13,200 | 8-10周 |
| 产品描述 | EP1013 is a broad-spectrum selective inhibitor of Caspase used in the study of type 1 diabetes. |
| 体内活性 | EP1013 therapy enhances functional syngeneic islet mass and promotes longevity of islet graft function.EP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit primary islet graft nonfunction, but the diabetes reversal rate for this group is not significantly different from the 3 mg/kg EP1013, 1 mg/kg EP1013, or 10 mg/kg zVAD groups. |
| 别名 | F1013 |
| 分子量 | 382.38 |
| 分子式 | C18H23FN2O6 |
| CAS No. | 223568-55-6 |
| Smiles | [C@@H](NC([C@@H](NC(OCC1=CC=CC=C1)=O)[C@H](C)C)=O)(C(CF)=O)CC(O)=O |
| 密度 | 1.258 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 60 mg/mL (156.91 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2.5 mg/mL (6.54 mM), Sonication is recommeded. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多